178 Immunosuppression and Hepatocellular Carcinoma Recurrence After Liver Transplantation

Rodríguez‐Perálvarez, Manuel; Pieri, Giulia; Naveas, M.C.; Tsochatzis, E.; García-Caparrós, Carmen; O'Beirne, J; Poyato-González, Antonio; Ferrín-Sa'nchez, G.; Patch, D.; Montero-Álvarez, José Luis; Thorburn, Douglas; Briceño, Javier; Mata, Manuel de la; Burroughs, A.K.

doi:10.1016/s0168-8278(13)60180-4

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the mean Tac trough blood concentration at 3 months was 8.2 in our population vs. 9.2 in Carenco study, and the overall mean Tac concentration at 3 months for patients with de novo malignancy was in our population 8.8 (+/-2.4) vs. 8.6 (+/-2.6) for patient without de novo cancer (10.8 vs. 8.9 in Carenco study). Regarding HCC recurrence, our results confirm that a reduced exposure to CNIs (for instance by using sirolimus) within the first months after LT could be associated with decreased risk of HCC recurrence [30,31]. Similarly, conversion from CNI to sirolimus is able to prevent squamous-cell carcinoma recurrence in kidney transplant recipients [32].…”

Section: Discussionsupporting

confidence: 73%